LA JOLLA, Calif., August 5, 2009 – Gary Chiang, Ph.D., and colleagues at Burnham Institute for Medical Research (Burnham) have elucidated how the stability of the REDD1 protein is regulated. The REDD1 protein is a critical inhibitor of the mTOR signaling pathway, which controls cell growth and proliferation. The study was published in the August 2009 issue of EMBO Reports .
As part of the cellular stress response, REDD1 is expressed in cells under low oxygen conditions (hypoxia). The Burnham scientists showed that the REDD1 protein rapidly undergoes degradation by the ubiquitin-proteasome system, which allowed for the recovery of mTOR signaling once oxygen levels were restored to normal.
"Cells initially shut down the most energy-costly processes, such as growth, when they're under hypoxic stress. They do this by expressing REDD1, which inhibits the mTOR pathway" said Dr. Chiang. "But when the cell needs the mTOR pathway active, REDD1 has to be eliminated first. Because the REDD1 protein turns over so rapidly, it allows the pathway to respond very dynamically to hypoxia and other environmental conditions."
Though the mTOR pathway has been the subject of significant study because of its frequent alteration in cancer, little was known about the regulation of REDD1. The team identified that a Cul4A-DDB1-ROC1-β-TRCP E3 ligase complex was responsible for targeting REDD1 for degradation. They also identified that REDD1 degradation was also dependent upon its phosphorylation by the protein kinase GSK3β. Because the inhibitory role of REDD1 in the mTOR pathway underscores its potential as a tumor suppressor, the team's studies suggest that increased proteolysis of REDD1 could be an additional way that mTOR signaling is upregulated in tumors.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. For the past decade (1999-2009), Burnham ranked first worldwide in the fields of biology and biochemistry for the impact of its research publications (defined by citations per publication), according to the Institute for Scientific Information.
Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit public benefit corporation. For more information, please visit www.burnham.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.